Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 544

Results For "UP"

7697 News Found

Infosys completes acquisition of BASE life science
Digitisation | September 02, 2022

Infosys completes acquisition of BASE life science

The acquisition reaffirms Infosys’ commitment to help global life sciences companies


NATCO Pharma to sell stake in Nativita and assets of Pharma division
News | September 02, 2022

NATCO Pharma to sell stake in Nativita and assets of Pharma division

NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord


Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility
News | September 02, 2022

Aurobindo Pharma to invest Rs 300 crore on mammalian cell culture manufacturing facility

The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers


Zydus receives final approval from USFDA for two tablets
Drug Approval | September 01, 2022

Zydus receives final approval from USFDA for two tablets

The group now has 322 approvals and has so far filed over 428 ANDAs since the commencement of the filing process in FY 2003-04


US FDA issues 17 observations for Biocon Biologics sites
News | September 01, 2022

US FDA issues 17 observations for Biocon Biologics sites

The observations primarily relate to the need for improving strategies for microbial control, enhancing quality oversight, augmenting the use of software applications & computerized tools


Bayer showcases cancer study data at ESMO Congress 2022
News | September 01, 2022

Bayer showcases cancer study data at ESMO Congress 2022

On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors


Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian
Clinical Trials | September 01, 2022

Bayer initiates Phase III study program to investigate oral FXIa inhibitor asundexian

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke


Medix Biochemica appoints former Roche executive to its Board of Directors
People | September 01, 2022

Medix Biochemica appoints former Roche executive to its Board of Directors

Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.


Merck India inaugurates R&D Excellence Centre in Bangalore
News | September 01, 2022

Merck India inaugurates R&D Excellence Centre in Bangalore

The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe


Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA
Clinical Trials | September 01, 2022

Daiichi Sankyo announces initiation of Phase 3 Trial of mRNA

COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan